ReviewViruses2015
Important Role of the IL-32 Inflammatory Network in the Host Response against Viral Infection.
Review in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- Lower Plasma IL-32 Levels Linked to Better Survival in Sepsis.Biomedicines · 2025Article
- Current Knowledge on the Interaction of Human Cytomegalovirus Infection, Encoded miRNAs, and Acute Aortic Syndrome.Viruses · 2023Review
- Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury.JCI insight · 2023Article
- 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson's disease are associated with LRRC37A/2 expression in astrocytes.Molecular neurodegeneration · 2022Article
- Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity.Frontiers in immunology · 2022Article
- Profound Treg perturbations correlate with COVID-19 severity.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Evaluation of interleukin-32 and cyclooxygenase-2 expression in HAM/TSP patients and HTLV-1 asymptomatic carriers.Iranian journal of basic medical sciences · 2021Article
- Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis.Communications biology · 2021Article
- Genetics and Functional Mechanisms of STAT3 Polymorphisms in Human Tuberculosis.Frontiers in cellular and infection microbiology · 2021Article
- Interleukin 32 expression in human melanoma.Journal of translational medicine · 2019Article
- Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis.Immune network · 2018Review
- The urinary and serum levels of IL-32 in children with febrile urinary tract infections.Future science OA · 2017Article
- Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients.Journal of cancer research and clinical oncology · 2017Article
- Genetic signature of strong recent positive selection at interleukin-32 gene in goat.Asian-Australasian journal of animal sciences · 2017Article
- Diminished COX-2/PGE2-Mediated Antiviral Response Due to Impaired NOX/MAPK Signaling in G6PD-Knockdown Lung Epithelial Cells.PloS one · 2016Article
- IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis.Mediators of inflammation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pro-inflammatory cytokine interleukin (IL)-32 has gained much attention recently because of its important role in the inflammatory network. Since the discovery of IL-32 in 2005, our appreciation for its diverse roles continues to grow. Recent studies have discovered the antiviral effects induced by IL-32 and its associated regulatory mechanisms. The interactions between IL-32 and various cytokines including cyclooxygenase 2 (COX-2), inducible nitric oxide synthase (iNOS), interferon (IFN)-λ1, interleukin (IL)-6, and soluble IL-6 receptor have been described. This review aims to integrate these new findings into explicit concepts and raises the intriguing possibility of IL-32 as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.